DEXLEVO, a company specializing in cosmetic medical devices, has completed pre-IPO funding of 26 billion won for existing investors, Magna Investment, Smilegate Investment, Hyundai Technology Investment, and Shinhan Capital. It is preparing for listing in 2023, and DEXLEVO has set a post value of 276 billion won after investment.
DEXLEVO was established in 2013 by Jaewon Yoo, a former researcher at Samyang Corporation, and succeeded in liquefying Polycaprolactone (PCL), a biodegradable polymer, for the first time in the world. Based on this technology, DEXLEVO developed a liquid PCL injection 'GOURI' and participated in the world's largest beauty fair AMWC (Aesthetic and Anti-aging Medicine world Congress) in September of last year and March of this year as a main sponsor to announce GOURI’s technological prowess and excellence. It will also participate in the International Master Course on Aging Science (IMCAS) held in Paris this June to spur marketing activities to increase its global market share.
Unlike existing fillers, as GOURI is in a liquid form without particulates, it spreads throughout the face when injected and induces collagen formation.
DEXLEVO is expanding its beauty market share with not only GOURI, a cosmetic medical device, but also KABELLINE, a contour product, and Touch BR, a whitening product. Currently, DEXLEVO is focusing on distribution in Southeast Asian regions such as Indonesia, Vietnam, and Thailand. KABELLINE is reaching the Americas.
KABELLINE is a contouring product that breaks down fat using deoxycholic acid. Unlike existing contouring products, there is no pain or side effects, and it is a product that fundamentally prevents the yo-yo effect from resynthesizing free fatty acids (FFA) remaining in the body into fat.
Touch BR is a whitening product with peptide and vitamin C as its main ingredients. It prevents skin aging and melanin production, and improves skin moisture. You can find more information on the DEXLEVO website (
www.dexlevoaesthetic.com).
